We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Genincode Plc | LSE:GENI | London | Ordinary Share | GB00BL97B504 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.125 | -1.41% | 8.75 | 8.50 | 9.00 | 8.875 | 8.75 | 8.875 | 168,343 | 15:02:44 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 1.43M | -5.56M | -0.0580 | -1.51 | 8.38M |
From Apr 2022 to Apr 2024
TIDMGENI
RNS Number : 7126A
GENinCode PLC
27 September 2022
GENinCode Plc
("GENinCode" or the "Company")
Interim results for six months ended 30 June 2022
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease ("CVD"), announces its unaudited interim results for the six months ended 30 June 2022. The first half of the 2022 saw GENinCode advance its US and UK commercial programmes for the introduction of its lead products whilst continuing to strengthen and increase revenues in its EU business.
Operational highlights (including post-period end)
-- Filing of FDA Pre-Submission for Cardio inCode(R) (Cardiovascular Disease Genetic Risk Score) for the onset of cardiovascular disease. Progressive discussions with the FDA in advance of the forthcoming 510K regulatory submission. The submission is expected to be filed with the FDA over the coming weeks.
-- Commissioning of GENinCode US CLIA lab (Clinical Laboratory Improvement Amendments) facility in Irvine, California. The CLIA lab application has now been submitted for Cardio inCode(R). The Company is accelerating the set-up of Lipid inCode(R) as a US lab diagnostic test (LDT) for the diagnosis of familial hypercholesterolemia (FH).
-- Preparation for roll-out of the Company's US Early Access Programs (EAPs) with its commercial partner EVERSANA Life Sciences LLC ("EVERSANA") to provide access to Cardio inCode(R) and Lipid inCode(R). First US product revenues are anticipated in 2023.
-- Indiana University collaboration representing flagship facilities in preparation for introduction of Cardio inCode(R) to US market.
-- Expansion of the research collaboration with Kaiser Permanente, California to assess Cardio inCode(R) for the polygenic risk assessment of CVD.
-- Milestone statement by American Heart Association (AHA) on the importance of Polygenic Risk Scores for future risk assessment of cardiovascular disease.
-- Collaboration with BUPA Cromwell Hospital, London for use of the Lipid inCode(R) test for FH and generation of first UK product revenues.
-- Successful completion and publication of Lipid inCode(R) NHS clinical study to improve diagnosis and turnaround time for testing of Familial Hypercholesterolemia (FH) at reduced cost to the NHS.
-- NHS implementation of Lipid inCode(R) with North East and Cumbria - Academic Health Science Network (NENC-AHSN) to diagnose FH - this represents the first commercial polygenic risk CVD test to be implemented by the NHS.
-- Completion of first COVID-19 Thrombo inCode(R) evaluation study for genetic predisposition to thrombosis - St Pau Hospital, Spain.
Financial highlights
-- Revenues increased 11% to GBP0.7m (2021: GBP0.6m). -- Adjusted EBITDA loss of GBP2.3m (2021: loss of GBP1.0m).
- Increased levels of investment in preparation for the launch of Lipid inCode(R) and Cardio inCode(R).
-- Cash of GBP12.4m at 30 June 2022 (2021: GBP1.0m).
- Reflecting the GBP15.3m of cash, net of expenses, raised at the IPO in July 2021 and tight cost control over the past year.
Recent developments
The Company also announces today:
-- First Cardio inCode(R) pilot implementation study in the Spanish region of Extremadura.
-- Acquisition of Abcodia Limited, Cambridge and its globally leading algorithmic technology for the Risk Assessment of Ovarian Cancer Algorithm (ROCA) test.
-- Commissioning of new UK lab operation and UKAS accreditation submission for Lipid inCode(R) to support the NHS implementation in NENC-AHSN.
Outlook for second half of 2022
GENinCode continues to advance its US 'soft launch' preparations for Cardio inCode(R) and Lipid inCode(R) via the roll-out of Early Access Programs (s) supported by the Company's new US CLIA lab facility in California. The Company remains focused on its US regulatory and reimbursement submissions for Cardio inCode(R) and will take advantage of existing reimbursement coverage for its globally leading familial hypercholesterolemia (FH) test Lipid inCode(R) .
Over the remainder of this financial year, the Company expects to complete the following key deliverables:
-- Finalise and file FDA regulatory submission for Cardio inCode(R) .
-- Advance Cardio inCode(R) clinical utility programmes to support reimbursement submissions planned in 2023.
-- Based on CMS local coverage determination and private payer reimbursement for FH, initiate the first US Early Access Programs/Physician Experience Programs for Lipid inCode(R) .
-- Strengthen the EVERSANA commercial, marketing and selling team in readiness for US product launch preparations.
-- Gain CLIA lab certification for Cardio inCode(R) and accelerate Lipid inCode(R) lab diagnostic test (LDT) service offering.
-- Commence first NHS (NENC-AHSN) patient tests as part of NHS implementation of Lipid inCode(R) and roll-out FH testing with the NHS via AHSN networks.
-- Advance COVID-19 Thrombo inCode(R) evaluation studies for genetic predisposition to thrombosis.
-- Continue to build our EU partnerships and develop our ongoing collaborative discussions with pharmaceutical companies. -- Increased Year-on-Year revenue growth.
Matthew Walls, Chief Executive Officer of GENinCode Plc said: "We are delivering on the plans set out at the IPO, with specific focus on the US approval, launch and revenue growth of Cardio inCode(R) and Lipid inCode(R). We are working closely with our US partner collaborators on launch planning and advancing our Early Access Programs prior to commencing sales in 2023. We have built a constructive dialogue with the FDA in preparation for our 510k regulatory filing.
"The commercialisation of Lipid inCode(R) continues to progress. Familial (inherited) Hypercholesterolemia (FH) is a key priority to address prevention of CVD in both the US and UK, and as such we are accelerating the US launch of Lipid inCode(R) to seize this opportunity in the space. The Lipid inCode(R) test has become the first polygenic test for CVD to be implemented by the UK NHS following the successful NHS clinical study announced earlier this year.
"We are also announcing today the acquisition of Abcodia Limited, Cambridge, and its Risk of Ovarian Cancer Algorithm (ROCA) test and technology, representing our first step into the oncology market. We will provide a further update on the Abcodia acquisition and the ROCA product and technology over the short term."
Analyst meeting, 12.30pm today
The Company will hold an analyst meeting 12.30pm (BST) on Tuesday, 27 September. Matthew Walls, CEO and Paul Foulger, CFO will host an in-person analyst meeting at the offices of Stifel at 150 Cheapside, London, EC2V 6ET to discuss the financial results and key topics including business strategy, partnerships, regulatory and reimbursement processes. Analysts interested in attending should contact Walbrook PR by emailing genincode@walbrookpr.com or calling 020 7933 8780.
Investor presentation, 4.30 pm today
The Company will also host a presentation for investors via the IMC platform at 4.30 pm BST on Tuesday, 27 September. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. To register for this, please use the following link:
https://www.investormeetcompany.com/genincode-plc/register-investor
For more information visit www.genincode.com
GENinCode Plc www.genincode.com or via Walbrook PR Matthew Walls, CEO Paul Foulger, CFO Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600 Alex Price / Ben Maddison / Richard Short Cenkos Securities Plc (Joint Broker) Tel: +44 (0)20 7397 8900 Giles Balleny Dale Bellis / Michael Johnson (Sales) Walbrook PR Limited Tel: 020 7933 8780 or Anna Dunphy / Louis Ashe-Jepson / Phillip Marriage genincode@walbrookpr.com
About GENinCode
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.
About Cardiovascular Disease
Cardiovascular disease (CVD) is the leading cause of death globally, taking an estimated 17.9 million lives each year. CVD is a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one third of these deaths occur prematurely in people under 70 years of age.
The most important behavioural risk factors of heart disease and stroke are unhealthy diet, physical inactivity, tobacco use and harmful use of alcohol. The effects of behavioural risk factors may show up in individuals as raised blood pressure, raised blood glucose, raised blood lipids, and overweight and obesity. These "intermediate risks factors" can be measured in primary care facilities and indicate an increased risk of heart attack, stroke, heart failure and other complications.
Cessation of tobacco use, reduction of salt in the diet, eating more fruit and vegetables, regular physical activity and avoiding harmful use of alcohol have been shown to reduce the risk of cardiovascular disease. Health policies that create conducive environments for making healthy choices affordable and available are essential for motivating people to adopt and sustain healthy behaviours.
Identifying those at highest risk of CVDs and ensuring they receive appropriate treatment can prevent premature deaths. Access to noncommunicable disease medicines and basic health technologies in all primary health care facilities is essential to ensure that those in need receive treatment and counselling.
CVD causes a quarter of all deaths in the UK and is the largest cause of premature mortality in deprived areas and is the single biggest area where the NHS can save lives over the next 10 years. CVD is largely preventable, through lifestyle changes and a combination of public health and NHS action on smoking and tobacco addiction, obesity, tackling alcohol misuse and food reformulation.
Genetic risk assessment can help early detection and treatment of CVD to help patients live longer, healthier lives. Many people are still living with undetected, high-risk conditions such as high blood pressure, raised cholesterol, and atrial fibrillation (AF). Progress continues in the NHS to identify and diagnose people routinely knowing their 'ABC' (testing and monitoring of AF, Blood pressure and Cholesterol) set out in the NHS 10 Year plan.
GENinCode Plc
Chief Executive's Statement
For the six months ended 30 June 2022
Introduction
On behalf of the Board, I am delighted to present the interim report for the six-month period ended 30 June 2022 for GENinCode Plc.
Following the IPO in July 2021, this statement provides an introduction to GENinCode, a summary of progress over the first half of the 2022 financial year and the outlook for the year ahead.
Introduction
GENinCode is engaged in the risk assessment, prediction, and prevention of cardiovascular disease (CVD). Our polygenic products and technology have been developed with the aim of prognosing and predicting the onset of CVD to deliver personalised treatment to improve patient outcomes. CVD accounts for around 18 million deaths annually, representing approximately 31 per cent. of all deaths worldwide with the global cost of CVD estimated to reach approximately $1.04 trillion by 2030.
CVD encompasses all conditions linked to the heart and blood vessels and is currently the leading cause of death globally. Four out of five deaths related to CVD are a result of heart attacks and strokes, and one third of these deaths occur prematurely in people under the age of 70. There are approximately 550 million people living with heart and circulatory diseases worldwide. This number has been rising due to changing lifestyles, ageing, and a growing population and improved survival rates from heart attacks and strokes.
In the US, CVD affects over 85 million people and accounts for more than one-third of all deaths. Common characteristics which put individuals at risk of CVD include raised blood pressure and high cholesterol levels, as well as obesity, lack of exercise and the co-occurrence of other diseases such as diabetes. Approximately 655,000 people in the US die from CVD each year, with coronary artery disease and heart attacks the most common.
The Company was incorporated in September 2018 to acquire the assets, intellectual property, and know-how of the Ferrer inCode and Gendiag.exe businesses, part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode(R) , Lipid inCode(R) , Thrombo inCode(R) and Sudd inCode(R) . Over EUR50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is now targeting the UK and US.
Multiple studies have shown that an individual's genetic load contributes between 40 to 50 per cent. to the development of CVD, highlighting genetics as one of the most significant contributing factors to the onset of cardiovascular disease.
The Company's product portfolio draws on advanced genomic precision testing using polygenic (multiple genes) technology, molecular testing, genotyping, sequencing, and AI bioinformatics to risk assess patient DNA. Through a simple blood or saliva sample, the Company can analyse the genetic variants and medical information associated with CVD to determine a patient's Genetic Risk Score (GRS) which is used to assess a patient's cardiovascular risk.
The current standard of care for primary prevention and assessment of the risk of CVD has been in use and largely unchanged for many years. Our polygenic risk assessment products for CVD are able to identify, risk assess and reclassify individuals traditionally categorised at 'low' or 'intermediate' risk who are in fact at a higher genetic risk of a CVD event (e.g. myocardial infarction/heart attack) than their current standard of care risk assessment suggests. This enables earlier in life preventative measures to be adopted to lower the future risk of a CVD event.
GENinCode has a strong and growing clinical evidence base, granted intellectual property portfolio with a vision to advance CVD risk assessment to more precisely align therapeutic treatment and lifestyle choices to improve patient outcomes.
Our products have commenced revenue generation in Europe. In July 2021 we successfully completed our admission to AIM and raised GBP15.3m net of expenses to accelerate business growth and internationally expand our commercial program.
Business review
Whilst the post-COVID markets and global economy remains challenging, our EU business strengthened over the first half with revenues increasing to GBP664k (H1 2021 GBP600k). The first half sales growth net of increased operating costs gave rise to an adjusted EBITDA loss of (GBP2.27m) (H1 2021: (GBP0.98m)), reflecting the growth in commercial investment across the group.
The first half saw the continued progress with the US Food and Drug Administration (FDA) following the Pre-Submission of Cardio inCode(R) (Cardiovascular Disease Genetic Risk Score) for the onset of cardiovascular disease. Productive discussions were held with the FDA earlier in the year and we are now preparing our final 510K regulatory submission. We expect the submission to be filed with the FDA over the coming weeks.
We have commenced set up of the GENinCode US CLIA lab (Clinical Laboratory Improvement Amendments) facility in Irvine, California, with the CLIA lab application now submitted for Cardio inCode(R). The CLIA lab is regulated by the FDA, Center for Medicaid Services (CMS) and Centers for Disease Control (CDC). Based on recent developments by the CDC to lift the genetic status for familial hypercholesterolemia (FH) in US public health, we have accelerated the set-up of our Lipid inCode(R) product as a US lab diagnostic test (LDT) for the diagnosis of FH.
We are working with our US commercial partner EVERSANA to prepare for the roll-out of our US Early Access Programs (EAPs) enabling selected physicians to access our Cardio inCode(R) and Lipid inCode(R) products. The EAP's will allow the initial 'soft launch' i.e. free of charge access, to our lead products with the start of US product revenues anticipated in 2023.
Over the first half we announced our collaboration with Indiana University (IU) School of Medicine, the largest US medical school, in preparation for the introduction of Cardio inCode(R) to US market. The program with IU will include testing Cardio inCode(R) alongside CT imaging. The first half also saw the announcement of the expansion of our research collaboration with Kaiser Permanente, California, to assess Cardio inCode(R) for the polygenic risk assessment of CVD. We have collaborated with Kaiser Permanente since 2014 and the ongoing Kaiser clinical studies are instrumental to growing our US population evidence base for Cardio inCode(R).
There have recently been some significant genetic advances in US health policies with a milestone statement by American Heart Association (AHA) on the importance of Polygenic Risk Scores for future risk assessment of cardiovascular disease. We expect to see continued support for the wider introduction of polygenic risk assessment products and technology for cardiovascular disease risk assessment.
In the UK, we announced a collaboration with BUPA Cromwell Hospital, London for use of our Lipid inCode(R) test for FH leading to the generation of our first UK product revenues. In the NHS we successfully completed and published our first Lipid inCode(R) NHS clinical study to improve diagnosis, turnaround time for testing of Familial Hypercholesterolemia (FH) at reduced cost to the NHS. Following the NHS publication, we announced the NHS implementation of Lipid inCode(R) with North East and Cumbria - Academic Health Science Network (NENC-AHSN). The Lipid inCode(R) implementation represents the first commercial polygenic risk CVD test to be adopted by the NHS. We have also recently completed the commissioning of our new lab based in London and submitted our UKAS accreditation application for Lipid inCode(R) to support the NHS.
We recently announced the completion of our first COVID-19 Thrombo inCode(R) evaluation study for patients with a genetic predisposition to thrombosis - St Pau Hospital, Spain. We are continuing to clinically assess the impact of thrombosis in the escalation of severe COVID-19 and expect to provide a further update later this year.
We have also recently announced the first Cardio inCode(R) pilot implementation study in the Spanish region of Extremadura. The Extremadura region has a population of 1 million, with an estimated 50,000 individuals at risk of a cardiovascular event, e.g. heart attack. Cardio inCode(R) is expected to change clinical practice by identifying those individuals at high genetic risk and improve preventative treatment. Successful completion of the pilot in over 500 individuals will lead to extension of the programme across the Extramadura region.
We are also announcing in today's interim report the acquisition of the entire issued share capital Abcodia Limited, Cambridge, and its Risk of Ovarian Cancer Algorithm (ROCA) test and technology. Based on a proven risk prediction of ovarian cancer and growing clinical evidence, we believe the ROCA test is the world's most accurate test for the early detection of familial ovarian cancer in BRCA+ genetically predisposed women. The ROCA test has been developed by the Abcodia team along with their NHS and US partners over the past 10 years and has recently completed its product development and EU regulatory approval. The ROCA test is poised to engage commercially in the UK, US and Europe and brings a breakthrough in monitoring for women at risk of ovarian cancer. Its algorithmic prediction of disease risk provides an exciting adjunct to our portfolio of risk prediction products for cardiovascular disease and represents our first step into the oncology market. Abcodia has been acquired with no upfront consideration on an earnout basis with a maximum payment of GBP1m to its institutional, VCT, university research and high net worth individual shareholders. The earnout is payable over a 6 Year earnout period up to the 31 July 2028 and is based on the ROCA test generating annual UK based EBIT of up to GBP1m (based on meeting two consecutive target EBITs of GBP350k and GBP650k respectively). Once each consecutive EBIT target has been achieved, a subsequent earnout payment of GBP350k and GBP650k respectively will be paid out of the Company's cash resources at the relevant time. Abcodia generated a loss before tax of GBP0.60m for the 12 months to 30 June 2022.
We will provide a further update on the Abcodia acquisition and the ROCA product and technology over the short term.
We have cash reserves of GBP12.4m at 30 June 2022 (2021: GBP1.0m) reflecting the GBP15.3m of cash, net of expenses, raised at the IPO in July 2021. We continue to maintain tight control over our investments commensurate with growth.
Financial review
Despite the continuing challenges of the COVID-19 pandemic, coupled with the deteriorating global economy, our EU revenues held up well with solid first half revenue growth to GBP664k (H1 2021: GBP600k). In summary, sales advanced to GBP664k with an adjusted EBITDA loss of (GBP2.27m) (H1 2021: (GBP0.98m)), the increased loss resulting from higher commercial and scale-up investment across the Group as we prepare to commercially expand in our core US, UK and EU growth markets.
Revenue
Revenue for the period was GBP664k (H1 2021: GBP600k), an increase of 10.7%. Spain continues to be the largest region for sales, followed by Italy and France. We reported our first sales in the UK (GBP12k), following the successful results announced for Lipid inCode(R) at the beginning of the year.
Gross profit
Gross profit was GBP283k (H1 2021: GBP320k). The gross profit margin decreased to 43% (H1 2021: 53%) due in part to pricing pressure for raw materials and increased contracted service provider costs.
Administrative expenses
In H1 2022, administrative expenses increased to GBP2.65m (H1 2021: GBP1.33m). The increase was largely caused by a) an increase in US commercialisation fees payable to EVERSANA (H1 2022: GBP790k v.s. H1 2021: GBP72k), and b) an increase in salary costs (H1 2022: GBP947k v.s. H1 2021: GBP613k), due to an increased headcount across the Group.
Operating loss and adjusted earnings before interest tax and depreciation
The Group generated an operating loss of GBP2.32m (H1 2021: (GBP1.01m)). We consider a more meaningful measure of underlying performance is obtained by examining adjusted EBITDA, which for H1 2022 was a loss of GBP2.27m (H1 2021: (GBP978k)). This excludes the effects of share-based payments of GBP57k (H1 2021: GBP17k). The increase in operating loss and adjusted EBITDA is caused by the increase in administrative expenses, resulting from the increased investment in personnel and other infrastructure costs in advance of the intended commercialisation expansion in the US, the EU, and the UK.
Tax
There is a tax charge of GBP4k (H1 2021: nil).
Fixed assets
We have capitalised, net of depreciation, a total of GBP193k (H1 2021: GBP9k) of property plant and equipment, reflecting investment in equipment required to fit out the UK laboratory. Additionally, we have capitalised, net of amortisation, GBP176k of intangible assets (H1 2021: GBP176k). This related to the application of new patents in various geographical regions which we believe will enhance the value of the business.
Cash and working capital
The cash position at 30 June 2022 was GBP12.40m (30 Jun 2021: GBP0.98m), reflecting the GBP15.3m of cash, net of expenses, raised at the time of the IPO in July 2021.
Capital structure
As at 30 June 2022, the Group had 95,816,866 shares in issue. No shares have been issued during the period.
Outlook for second half of 2022
GENinCode continues to advance its US 'soft launch' preparations for Cardio inCode(R) and Lipid inCode(R) via the roll-out of Early Access Programs (EAPs) supported by the Company's new US CLIA lab facility in California. The Company remains focused on our US regulatory and reimbursement submissions for Cardio inCode(R) and will take advantage of the existing reimbursement coverage for Familial Hypercholesterolemia (FH) testing by accelerating the set-up of Lipid inCode(R) , our globally leading FH test.
Over the remainder of this financial year, the Company expects to complete the following key deliverables:
-- Finalisation and filing of FDA 510K regulatory submission for Cardio inCode(R) .
-- Advance Cardio inCode(R) clinical utility programs to support our reimbursement submissions planned in 2023.
-- Based on CMS local coverage determination and private payer reimbursement for FH, initiate the first US Early Access Programs (EAPs) for Lipid inCode(R) .
-- Strengthen the EVERSANA commercial, marketing and selling team in readiness for US product launch.
-- Gain CLIA lab certification for Cardio inCode(R) and accelerate Lipid inCode(R) lab diagnostic test (LDT) service offering.
-- Commence first NHS (NENC-AHSN) patient tests as part of the NHS implementation of Lipid inCode(R) and roll-out FH testing with the NHS via AHSN networks.
-- Advance COVID-19 Thrombo inCode(R) evaluation studies for genetic predisposition to thrombosis.
-- Continue to build our EU partnerships and develop our ongoing collaborative discussions with pharmaceutical companies. -- Implementation of the Cardio inCode(R) pilot in Extremadura, Spain. -- Increased Year-on-Year revenue growth.
We continue to deliver the plans set out at the IPO last year with specific focus on our US product launch and growth of Cardio inCode(R) for the prevention of cardiovascular disease. Based on the US Centres for Disease Control (CDC) escalation of Familial Hypercholesterolemia (FH) genetic testing to a Tier 1 public health status, we will accelerate our launch plans for Lipid inCode(R) for the management of FH.
We are working closely with our US partner collaborators on launch planning and advancing our Early Access Programs prior to anticipated sales in 2023. We have built a constructive dialogue with the FDA in preparation for our 510K regulatory filing for Cardio inCode(R).
In the UK, following the successful NHS clinical studies and pilot programme we are now implementing Lipid inCode(R) (familial hypercholesterolemia testing) in the North of England NENC-AHSN. We continue to strengthen our EU business and anticipate continued year-on-year revenue growth in in the second half of 2022.
Following today's announcement of the acquisition of Abcodia Limited, Cambridge, and its Risk of Ovarian Cancer Algorithm (ROCA) test and technology, we are preparing plans to accelerate revenues for the ROCA product in the UK and for market entry in the US and EU.
Matthew Walls
Chief Executive Officer
27 September 2022
GENinCode Plc
Consolidated Statement of Comprehensive Income
For the six months ended 30 June 2022
Hot Features
Premium
Unaudited Unaudited Audited
6 months 6 months Year ended
to to
Notes 30-Jun 30-Jun 31-Dec-21
2022 2021
GBP'000 GBP'000 GBP'000
-------------------------------------- ------ ---------- ---------- -----------
Continuing operations
Revenue 664 600 1,154
Cost of sales (381) (280) (561)
-------------------------------------- ------ ---------- ----------
Gross profit 283 320 593
Administrative expenses (2,556) (1,298) (4,019)
ADJUSTED EBITDA (2,273) (978) (3,426)
Depreciation and amortisation (33) (15) (35)
Loss on disposal of fixed
assets - - (19)
Share-based payments (56) (17) (73)
Listing costs - - (584) Non-recurring expenditure - - (9) -------------------------------------- ------ ---------- ---------- ----------- Operating Loss (2,362) (1,010) (4,146) Finance Income 38 - 10 -------------------------------------- ------ ---------- ---------- ----------- Loss on ordinary activities before taxation (2,324) (1,010) (4,136) Corporation tax payable 4 (4) - (6) -------------------------------------- ------ ---------- ---------- ----------- Loss after taxation (2,328) (1,010) (4,142) -------------------------------------- ------ ---------- ---------- ----------- Other comprehensive (expenses) / income Items that will not be reclassified to profit or loss: Exchange differences arising on translating foreign operation (253) (5) 72 -------------------------------------- ------ ---------- ---------- ----------- Other comprehensive (expenses) / income for the period, net of income tax (253) (5) 72 -------------------------------------- ------ ---------- ---------- ----------- Total comprehensive loss for the period (2,581) (1,015) (4,070) ====================================== ====== ========== ========== =========== Loss per ordinary share attributable to the owners of the parent 6 Pence Pence Pence during the period Basic (2.7) (887.8) (8.1) Diluted (2.7) (887.8) (8.1)
GENinCode Plc
Consolidated Statement of Financial Position
As at 30 June 2022
Unaudited Unaudited Audited
As at As at As at
30-Jun 30-Jun 31-Dec
Notes 2022 2021 2021
GBP'000 GBP'000 GBP'000
----------------------------- ------ ---------- ---------- --------
Non-current assets
Intangible assets 176 176 193
Property, plant &
equipment 193 9 46
Total non-current
assets 369 185 239
----------------------------- ------ ---------- ---------- --------
Current assets
Inventory 34 10 14
Trade and other receivables 501 234 399
Financial assets - - 4
Cash and bank balances 12,398 978 14,554
Total current assets 12,933 1,222 14,971
----------------------------- ------ ---------- ---------- --------
Total Assets 13,302 1,407 15,210
============================= ====== ========== ========== ========
Equity
Share capital 5 958 114 958
Share premium 15,551 3,279 15,551
Share based payment
reserve 158 17 73
Exchange movements
reserve (184) (8) 69
Retained deficit (5,261) (2,580) (2,933)
11,222 822 13,718
----------------------------- ------ ---------- ---------- --------
Liabilities
Non-current liabilities
Trade and other payables 1,268 - 661
Current liabilities
Trade and other payables 802 585 825
Deferred tax 10 - 6
Total liabilities 2,080 585 1,492
----------------------------- ------ ---------- ---------- --------
Total equity and
liabilities 13,302 1,407 15,210
============================= ====== ========== ========== ========
GENinCode Plc
Consolidated Statement of Cash Flows
For the six months ended 30 June 2022
Unaudited Unaudited Audited
6 months 6 months Year
to to ended
30-Jun 30-Jun 31-Dec
2021
2022 2021
Notes GBP'000 GBP'000 GBP'000
------------------------------------------ ------- ---------- ---------- --------
Cash flows from operating activities
Loss before taxation (2,328) (1,010) (4,137)
Adjustments for:
Foreign exchange loss/gain (126) - 136
Share based charged adjustment 57 17 73
Depreciation and amortization 33 15 35
Loss on disposal - - 19
Movement in translation/retranslation (253) (5) 72
Taxation 4 - 6
Operating loss before working
capital changes (2,613) (983) (3,796)
--------------------------------------------------- ---------- ---------- --------
Cash used in operations
Decrease / (Increase) in trade
and other receivables (102) 15 (150)
(Decrease) / Increase in trade
and other payables 584 (21) 922
Decrease/(Increase) in inventory (20) 8 4
Decrease/(Increase) in financial
assets 4 (2)
Net cash outflow from operating
activities (2,147) (981) (3,022)
--------------------------------------------------- ---------- ---------- --------
Investing activities
Purchase of property, plant and
equipment (162) (1) (41)
Purchase of intangible assets - (51) (104)
Net cash flows used in investing
activities (162) (52) (145)
--------------------------------------------------- ---------- ---------- --------
Financing activities
Issue of ordinary shares (net
of issue expenses) - - 15,856
Net cash flows from financing
activities - - 15,856
--------------------------------------------------- ---------- ---------- --------
Net change in cash and cash equivalents (2,309) (1,033) 12,689
Cash and cash equivalents at the
beginning of the period 14,554 2,003 2,003
Exchange gains/(losses) on cash
and cash equivalents 153 8 (138)
Cash and cash equivalents at the
end of the period 12,398 978 14,554
--------------------------------------------------- ---------- ---------- --------
GENinCode Plc
Consolidated Statement of Changes in Equity
For the six months ended 30 June 2022
Share Share Retained Translation Other Total
capital premium profits reserve reserves equity
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
----------------------------- -------- -------- --------- ------------ --------- --------
Balance at 1 Jan 2021 114 3,318 (1,570) (3) - 1,859
Other comprehensive income - - - (5) - (5)
Loss for the period ended
30 June 2021 - - (1,010) - - (1,010)
Capitalisation of IPO costs - (39) - - - (39)
Share based payments - - - - 17 17
----------------------------- -------- -------- --------- ------------ --------- --------
Balance at 30 June 2021 114 3,279 (2,580) (8) 17 822
----------------------------- -------- -------- --------- ------------ --------- --------
Reduction of share premium - (2,779) 2,779 - - -
Bonus share issue 458 (458) - - - -
Issue of share capital 386 16,653 - - - 17,039
Costs of share issue - (1,144) - - - (1,144)
Share based payments - - - - 56 56
Other comprehensive income - - - 77 77 Loss for the period ended 31 December 2021 - - (3,132) - - (3,132) ----------------------------- -------- -------- --------- ------------ --------- -------- Balance at 31 December 2021 958 15,551 (2,933) 69 73 13,718 ----------------------------- -------- -------- --------- ------------ --------- -------- Other comprehensive income - - - (253) - (253) Loss for the six months ended 30 June 2022 - - (2,328) - (2,328) Share based payments - - - - 85 85 ----------------------------- -------- -------- --------- ------------ --------- -------- Balance at 30 June 2022 958 15,551 (5,261) (184) 158 11,222 ----------------------------- -------- -------- --------- ------------ --------- -------- Share capital is the amount subscribed for shares at nominal value. Share premium is the amount subscribed for share capital in excess of nominal value less share issue costs. Other reserves arise from the share options issued by the company during the year ended 31 December 2021. Retained earnings represents accumulated profit or losses to date.
GENinCode Plc
Notes to the Consolidated Financial Statements
For the six months ended 30 June 2022
1. General information
GENinCode plc (the "Company") is a public limited company admitted to trading on the AIM market of the London Stock Exchange on 22 July 2021. The Company is incorporated and domiciled in England and Wales. The registered office of the Company is One, St. Peters Square, England, M2 3DE. The registered company number is 11556598.
The Company was incorporated on 06 September 2018.
The Company's principal activity is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes.
The financial information set out in this half yearly report does not constitute statutory accounts as defined in Section 434 of the Companies Act 2006. The statutory financial statements for the year ended 31 December 2021, prepared under UK adopted International Financial Reporting Standards ("IFRS"), have been filed with the Registrar of Companies. The auditor's report on those financial statements was unqualified and did not contain statements under Sections 498(2) and 498 (3) of the Companies Act 2006.
Copies of the annual statutory accounts and the Interim Report can be found on the Company's website at www.genincode.com.
2. Significant accounting policies and basis of preparation 2.1 Statement of compliance
This half yearly report has been prepared using the historical cost convention, on a going concern basis and in accordance with UK adopted International Financial Reporting Standards ("IFRS"), IFRS Interpretations Committee (IFRIC) and the Companies Act 2006 applicable to companies reporting under IFRS, using accounting policies which are consistent with those set out in the financial statements for the year ended 31 December 2021.
2.2 Application of new and revised UK adopted International Financial Reporting Standards (IFRSs)
There are no IFRSs or IFRIC interpretations that are effective for the first time in this financial period that would be expected to have a material impact on the Company.
3. Segmental reporting
The Company has one reportable segment, namely that is the development and commercialisation of clinical genetic tests, to provide predictive analysis of risk to a patient's health based on their genes, the geographical split of revenue generation is below.
6 months 6 months 12 months
to to to
Turnover by geographical generation 30-Jun-22 30-Jun-21 31-Dec-21
GBP'000 GBP'000 GBP'000
--------------------------------------- ---------- ---------- ----------
UK 12 - -
Spain 652 600 1,154
US - - -
664 600 1,154
---------------------------------------- ---------- ---------- ----------
GENinCode Plc
Notes to the Consolidated Financial Statements (cont.)
For the six months ended 30 June 2022
4 Taxation
6 months 6 months 12 months
to to to
Income taxes recognised in profit 30-Jun-22 30-Jun-21 31-Dec-21
or loss
GBP'000 GBP'000 GBP'000
----- ------------------------------------ ---------- ---------- ----------
Current tax
GEN inCode SLU 4 - 6
------------------------------------------- ---------- ----------
Tax credit for the period 4 - 6
------------------------------------------- ---------- ---------- ----------
5 Share capital
Issued share capital comprises 30-Jun-22 30-Jun-21 31-Dec-21
GBP'000 GBP'000 GBP'000
----- ------------------------------------ ---------- ---------- ----------
95,816,866 Ordinary shares of
GBP0.01 each 958 958
76,549 Ordinary shares of GBP1
each 76
37,902 B Ordinary shares of GBP1
each 38
------------------------------------------- ---------- ---------- ----------
6 Loss per share
6 months 6 months 12 months
to to to
30-Jun-22 30-Jun-21 31-Dec-21
GBP'000 GBP'000 GBP'000
----- ------------------------------------ ---------- ---------- ----------
Basic and diluted loss per share
Loss after tax (GBP) (2,581) (1,015) (4,070)
Weighted average number of shares 95,817 114 50,552
Basic and diluted loss per share
(pence) (2.7) (887.8) (8.1)
------------------------------------------- ---------- ---------- ----------
As the Company is reporting a loss from continuing operations
for the period then, in accordance with IAS 33, the share options
are not considered dilutive because the exercise of the share
options would have an anti-dilutive effect. The basic and diluted
earnings per share as presented on the face of the income statement
are therefore identical.
7 Events after the reporting
date
The Company has evaluated all events and transactions that occurred
after 30 June 2022 up to the date of signing of the financial
statements.
The Company believes there are no reportable events post reporting
date.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IR EAPNKASLAEFA
(END) Dow Jones Newswires
September 27, 2022 02:01 ET (06:01 GMT)
1 Year Genincode Chart |
1 Month Genincode Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
